Literature DB >> 15227412

Comparison of acute rejection in sensitized ("domino") and unsensitized donor hearts following heterotopic transplantation.

A Schuetz1, M Breuer, M Engelhardt, U Brandl, C Hammer, B M Kemkes.   

Abstract

Right cervical heart transplantation was performed in 18 mongrel dogs. Three experimental groups (6 dogs in each) were set up. Group I and II dogs received unsensitized donor hearts, while Group III dogs received the potentially sensitized native hearts of Group I and II dogs, following final rejection episodes in those animals. We call the transplantation of a native heart out of a previous recipient "domino" transplantation. Immunosuppression consisted of standard triple-drug therapy in all dogs. Groups II and III received, additionally, high-dose steroids during acute rejection episodes. The donor hearts were assessed daily via transmural biventricular biopsy (graded according to Billingham's criteria), and these results were compared with results of daily cytoimmunologic monitoring (n=259 for activation-index), used as a noninvasive method. Supplementally, antimyosin scintigraphy (n=25, heart-to-lung ratio) was employed for rejection diagnosis. The rejection type was determined by calculating T-cell/B-cell ratios with the aid of fluorescein-conjugated monoclonal antibodies. The invasive data consisted of 587 transmyocardial biopsy results, which were used to establish the rejection kinetics. In the domino grafts of Group III, acute rejection had an earlier onset (an average of 3.2 days) and was permanent, despite repeated cortisonepulse therapy. In contrast, acute rejection followed a biphasic course in Group II (average rejection-free interval, 6.8 days) and was non-uniform in Group I (onset after an average of 5.7 days). Cytoimmunologic monitoring corresponded significantly (p < 0.001) with daily histologic findings in Groups I and II, but not with those in Group III (domino grafts). The T-cell/B-cell ratio increased in Groups I and II (to an average of 3.9), as would be expected during acute cellular rejection. In contrast, the T-cell/B-cell ratio decreased in Group III (to an average of 1.1). The heart-to-lung ratio, as determined by antimyosin scintigraphy, accurately revealed the various stages of acute rejection in all groups (p < 0.001). We conclude that the native heart appears to become sensitized during acute rejection episodes of a heterotopically transplanted heart. Cytoimmunologic monitoring and calculation of T-cell/B-cell ratios support this conclusion. In addition, we conclude that cyto-immunologic monitoring and antimyosin scintigraphy are highly specific and sensitive tools for diagnosis of cellular rejection.

Entities:  

Year:  1991        PMID: 15227412      PMCID: PMC326354     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  10 in total

1.  Indium-111 monoclonal antimyosin for diagnosis of cardiac rejection.

Authors:  A Schütz; S Fritsch; C Kugler; M Anthuber; F Sudhoff; K Wenke; C Spes; C Angermann; J M Gokel; B M Kemkes
Journal:  Transplant Proc       Date:  1990-08       Impact factor: 1.066

2.  Studies of surface immunoglobulins on human B lymphocytes. I. Dissociation of cell-bound immunoglobulins with acid pH or at 37 degrees C.

Authors:  K Kumagai; T Abo; T Sekizawa; M Sasaki
Journal:  J Immunol       Date:  1975-10       Impact factor: 5.422

3.  The Registry of the International Society for Heart Transplantation: fifth official report--1988.

Authors:  L S Fragomeni; M P Kaye
Journal:  J Heart Transplant       Date:  1988 Jul-Aug

4.  Antibodies in the serum and on the heart of dogs with cardiac allografts.

Authors:  B S Goldman; K H Shumak; M D Silver; J Cartier; W Lixfeld; W G Bigelow; J H Crookston
Journal:  Transplant Proc       Date:  1971-03       Impact factor: 1.066

5.  Heterotopic cardiac transplantation in dogs.

Authors:  B K Semb
Journal:  Scand J Thorac Cardiovasc Surg       Date:  1971

6.  Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody.

Authors:  B A Khaw; H K Gold; T Yasuda; R C Leinbach; M Kanke; J T Fallon; M Barlai-Kovach; H W Strauss; F Sheehan; E Haber
Journal:  Circulation       Date:  1986-09       Impact factor: 29.690

7.  Imaging of cardiac allograft rejection in dogs using indium-111 monoclonal antimyosin Fab.

Authors:  L J Addonizio; R E Michler; C Marboe; P E Esser; L L Johnson; D W Seldin; W M Gersony; P O Alderson; E A Rose; P J Cannon
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

8.  The present status of heterotopic cardiac transplantation.

Authors:  C N Barnard; M S Barnard; D K Cooper; C A Curchio; J Hassoulas; D Novitsky; A Wolpowitz
Journal:  J Thorac Cardiovasc Surg       Date:  1981-03       Impact factor: 5.209

9.  Cytoimmunological monitoring in acute rejection and viral, bacterial or fungal infection following transplantation.

Authors:  W Ertel; H Reichenspurner; C Lersch; C Hammer; M Plahl; M Lehmann; B M Kemkes; G Osterholzer; B Reble; B Reichart
Journal:  J Heart Transplant       Date:  1985 Jul-Aug

10.  Surface immunoglobulins on thymus and thymus-derived lymphoid cells.

Authors:  A D Bankhurst; N L Warner; J Sprent
Journal:  J Exp Med       Date:  1971-10-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.